NEW YORK, Jan 14 (Reuters) - Wyeth said on Wednesday about a dozen European regulators have analyzed data from mid-stage trials of its bapineuzumab drug for Alzheimer's disease and are satisfied that it is appropriate to move ahead with larger late-stage studies.
